$Venetoclax added to CLAG regimen might improve the outcome of patients with relapsed/refractory acute myeloid leukemia$

Venetoclax added to CLAG regimen might improve the outcome of patients with relapsed/refractory acute myeloid leukemia

Background: We aim to analyze the efficacy and safety of Venetoclax (Ven) added to cladribine + cytarabine + granulocyte colony-stimulating factor (G-CSF) ± idarubicin or mitoxantrone (CLAG ± Ida/Mito) regimen as a salvage treatment of relapsed/refractory acute myeloid leukemia (RR-AML). Methods: A...

Full description

Saved in:

Bibliographic Details
Main Authors:	Yu Zhang, Zhao Yin, Zurong Yao, Dan Xu, Xuejie Jiang, Xiaqi Nie, Dandan Chen, Hongsheng Zhou, Pengcheng Shi, Hui Liu, Qifa Liu, Guopan Yu
Format:	Article
Language:	English
Published:	SAGE Publishing 2025-02-01
Series:	Therapeutic Advances in Hematology
Online Access:	https://doi.org/10.1177/20406207251319603
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Outcomes of Six-Dose High-Dose Cytarabine as a Salvage Regimen for Patients with Relapsed/Refractory Acute Myeloid Leukemia
by: Brandi Anders, et al.
Published: (2017-01-01)

Hemophagocytic lymphohistiocytosis secondary to refractory acute myeloid leukemia resolved after second line treatment with azacitidine plus venetoclax
by: Claudio Fozza
Published: (2024-01-01)

Venetoclax-based salvage therapy as a bridge to transplant is feasible and effective in patients with relapsed/refractory AML
by: Julia M. Unglaub, et al.
Published: (2025-01-01)

Valproic Acid Enhances Venetoclax Efficacy in Targeting Acute Myeloid Leukemia
by: Renshi Kawakatsu, et al.
Published: (2025-01-01)

Real-life outcome after failure to venetoclax and hypomethylating-based therapy for acute myeloid leukemia
by: Carlos Jiménez-Vicente, et al.
Published: (2025-01-01)

Age-Adjusted Schedules of Venetoclax and Hypomethylating Agents to Treat Extremely Elderly Patients with Acute Myeloid Leukemia
by: Aaron M. Lee, et al.
Published: (2022-01-01)

Left Kidney Undifferentiated Spindle Cell Sarcoma with Myeloid Cell Leukemia-1 Amplification: Therapeutic Response to Bortezomib, Venetoclax, and Dexamethasone Therapy
by: Cheng-Yu Tang, et al.
Published: (2023-10-01)

Sacral Myeloid Sarcoma Manifesting as Radiculopathy in a Pediatric Patient: An Unusual Form of Myeloid Leukemia Relapse
by: Joana Ruivo Rodrigues, et al.
Published: (2018-01-01)

Chronic Myeloid Leukemia Relapsing 25 Years after Allogenic Stem Cell Transplantation
by: Håkon Reikvam, et al.
Published: (2018-01-01)

Venetoclax plus low-intensity chemotherapy for adults with acute lymphoblastic leukemia
by: Marlise R. Luskin, et al.
Published: (2025-02-01)

Efficacy of Venetoclax and Dexamethasone in Refractory IgM Primary Plasma Cell Leukemia with t(11;14) and TP53 Mutation: A Case Report and Literature Review
by: Salimah Valliani, et al.
Published: (2020-01-01)

Olutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: a multicohort open-label phase 1/2 trial
by: Jorge E. Cortes, et al.
Published: (2025-01-01)

Myelodysplastic Syndrome with Transfusion Dependence Treated with Venetoclax
by: Waqas Jehangir, et al.
Published: (2020-01-01)

Isolated central nervous system relapse in blast crisis of chronic myeloid leukemia: a case report
by: Hari Priya Raghvan, et al.
Published: (2025-01-01)

The Use of Imatinib Mesylate as a Lifesaving Treatment of Chronic Myeloid Leukemia Relapse after Bone Marrow Transplantation
by: Monika Conchon, et al.
Published: (2009-01-01)

Refractory and relapsing forms of <i>Clostridium difficile</i>-associated colitis
by: A. A. Sheptulin
Published: (2011-03-01)

Remission of Severe, Relapsed, and Refractory TTP after Multiple Cycles of Bortezomib
by: Manu R. Pandey, et al.
Published: (2017-01-01)

Is There a Role for Daratumumab Retreatment in Patients with Relapsed/Refractory Multiple Myeloma?
by: Davor Galusic, et al.
Published: (2025-01-01)

You Might Not Remember Reading This
by: Robert Schaller, et al.
Published: (2023-05-01)

The Role of Allogeneic Stem Cell Transplantation in Relapsed/Refractory Hodgkin's Lymphoma Patients
by: Evgeny Klyuchnikov, et al.
Published: (2011-01-01)

Retreatment with Bendamustine-Bortezomib-Dexamethasone in a Patient with Relapsed/Refractory Multiple Myeloma
by: Claudio Cerchione, et al.
Published: (2016-01-01)

PD-1 Checkpoint Blockade in Patients for Acute Myeloid Leukemia after HSCT Relapse Resulted in Severe GVHD and sHLH
by: Zhi zhuo Du, et al.
Published: (2022-01-01)

Safety and efficacy of anti-CD30 CAR-T cell therapy in relapsed/refractory classic Hodgkin lymphoma: a systematic review and meta-analysis
by: Fanqiao Meng, et al.
Published: (2025-01-01)

Utilisation of an in vivo malaria model to provide functional proof for RhopH1/CLAG essentiality and conserved orthology with P. falciparum
by: Mitchell L. Trickey, et al.
Published: (2025-02-01)

The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development
by: Pralay Mukhopadhyay, et al.
Published: (2025-02-01)

Treatment Interruption and Regimen Change in Firstgeneration versus Second-generation Tyrosine Kinase Inhibitors used as First-line Therapy for Chronic Myeloid Leukemia
by: Melea A. Ward, et al.
Published: (2015-04-01)

Patient Preferences for Chronic Myeloid Leukemia Medication Regimen Attributes and their Potential Impact on Adherence: Results from a Multi-national Conjoint Study
by: Ishan Hirji, et al.
Published: (2014-09-01)

The MADS-Box Transcription Factor ClAG2 Is a Key Regulator for the Formation of Double Flower in <i>Clematis</i> L.
by: Xuerong Chen, et al.
Published: (2024-12-01)

Short‐Course Blinatumomab Treatment as a Bridge to Further Salvage Therapy for Relapsed/Refractory B‐Cell Acute Lymphoblastic Leukemia: A Retrospective Single‐Center Study
by: Jin Yin, et al.
Published: (2024-12-01)

Multinational retrospective analysis of bridging therapy prior to chimeric antigen receptor t cells for relapsed/refractory acute lymphoblastic leukemia in children and young adults
by: Maike Breidenbach, et al.
Published: (2025-01-01)

Impact of prior CAR T-cell therapy on mosunetuzumab efficacy in patients with relapsed or refractory B-cell lymphomas
by: Elise A. Chong, et al.
Published: (2025-02-01)

A Cost-effectiveness Analysis of Brentuximab Vedotin in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma
by: Margaret Hux, et al.
Published: (2016-10-01)

Outcomes of Idecabtagene Vicleucel Therapy in Patients with Relapsed/Refractory Multiple Myeloma: A Single-Institution Experience
by: Aaron Trando, et al.
Published: (2024-12-01)

Acute Myeloid Leukemia Presenting as Myeloid Sarcoma with a Predisposition to the Gynecologic Tract
by: Ryan M. Kahn, et al.
Published: (2019-01-01)

Combination of Dabrafenib and Trametinib for the Treatment of Relapsed and Refractory Multiple Myeloma Harboring BRAF V600E Mutation
by: Rūta Čepulytė, et al.
Published: (2020-01-01)

Global outcomes and prognosis for relapsed/refractory mature T-cell and NK-cell lymphomas: results from the PETAL consortium
by: Jessy Xinyi Han, et al.
Published: (2025-02-01)

CPSF6-RARγ interacts with histone deacetylase 3 to promote myeloid transformation in RARG-fusion acute myeloid leukemia
by: Tianhui Liu, et al.
Published: (2025-01-01)

Efficacy and safety of currently approved and lower starting doses of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukemia: a phase IV study
by: Muhit Özcan, et al.
Published: (2025-01-01)

Bone marrow immune cells and drug resistance in acute myeloid leukemia
by: Miao Zhang, et al.
Published: (2025-02-01)

Primary tumor resection might improve outcomes in metastatic thoracic esophageal cancer
by: Jiayan Wu, et al.
Published: (2025-01-01)